- Home
- GRNT vs GHRS Comparison
GRNT vs GHRS Comparison
Compare GRNT & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- GHRS
- Stock Information
- Founded
- GRNT 2013
- GHRS 2018
- Country
- GRNT United States
- GHRS Ireland
- Employees
- GRNT N/A
- GHRS N/A
- Industry
- GRNT Blank Checks
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- GHRS Health Care
- Exchange
- GRNT Nasdaq
- GHRS Nasdaq
- Market Cap
- GRNT 675.9M
- GHRS 774.1M
- IPO Year
- GRNT N/A
- GHRS 2021
- Fundamental
- Price
- GRNT $5.20
- GHRS $12.54
- Analyst Decision
- GRNT Buy
- GHRS Strong Buy
- Analyst Count
- GRNT 1
- GHRS 9
- Target Price
- GRNT $8.00
- GHRS $29.33
- AVG Volume (30 Days)
- GRNT 377.8K
- GHRS 269.0K
- Earning Date
- GRNT 11-06-2025
- GHRS 11-07-2025
- Dividend Yield
- GRNT 8.46%
- GHRS N/A
- EPS Growth
- GRNT N/A
- GHRS N/A
- EPS
- GRNT 0.25
- GHRS N/A
- Revenue
- GRNT $409,332,000.00
- GHRS N/A
- Revenue This Year
- GRNT $35.82
- GHRS N/A
- Revenue Next Year
- GRNT $10.41
- GHRS N/A
- P/E Ratio
- GRNT $21.14
- GHRS N/A
- Revenue Growth
- GRNT 10.32
- GHRS N/A
- 52 Week Low
- GRNT $4.52
- GHRS $6.72
- 52 Week High
- GRNT $7.00
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- GRNT 44.35
- GHRS 42.79
- Support Level
- GRNT $5.13
- GHRS $12.40
- Resistance Level
- GRNT $5.32
- GHRS $14.44
- Average True Range (ATR)
- GRNT 0.13
- GHRS 0.90
- MACD
- GRNT -0.01
- GHRS -0.03
- Stochastic Oscillator
- GRNT 22.43
- GHRS 5.60
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.